tirzepatide psychological effects Men before and after tirzepatide: real results, timelines, and what to expect tirzepatide mental health side effects

Here's a real-world comparison of the weight loss data we have: Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in the STEP 1 trial Tirzepatide 15 mg (Zepbound): ~22.5% body weight loss at 72 weeks in SURMOUNT-1 Retatrutide 12 mg: ~24.2% body weight loss at 48 weeks in Phase 2 (shorter trial, remember) Promising, but still unproven at scale

Recent Mergers & Acquisitions (M & A) 2025-2026: Mar 2026: BioMarin Pharmaceutical agreed to acquire rare disease biotech Amicus Therapeutics for $4.8B, strengthening metabolic & rare disease franchise overlap with diabetes-associated disorders Mar 2026: Sanofi entered $2.2B acquisition deal for Dynavax Technologies to expand vaccine and immunometabolic pipeline supporting diabetes-comorbidity therapeutics Jan 2026: Eli Lilly and Company announced acquisition of Ventyx Biosciences for $1.2B, expanding cardiometabolic and diabetes-related pipeline into immunology-linked therapies 2026 (closed/announced): Merck & Co

Increased norepinephrine levels can promote satiety and reduce food intake, while higher dopamine levels may help control cravings and regulate reward pathways associated with food consumption

On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, citing no clinical need for large-scale compounding now that FDA-approved supply is stable

(16) Diving deeper, the team sought to unravel the effects of this compound on the contractile dynamics of gastric smooth muscles when exposed to acetylcholine and electrical field stimulation